Kyle Hunter retweeted
We've been playing "Whack-A-Mole" with new SARS-2 variants.
Elegant, anti-fragile approaches are necessary moving forward. It's worth noting the boneyard of *No Longer Supported/Authorized* treatments on BARDA's webpage:
$HGEN
Just something interesting from BARDA's Strategic Plan for 2022-2026
medicalcountermeasures.gov/...
Pg12:
"Achieving FDA approval of two threat-agnostic and host-directed therapeutics for severe
disease by targeting potential organ damage”
So now the @ThoraxBMJ, @LancetRespirMed, @NIH, and @MayoClinic have tweeted about @humanigen. @US_FDA do you need them to be tweeted by anyone else for them to get EUA? I think all the boxes are checked at this point. $hgen #lenzilumab P.S.. it is Variant Agnostic..
Kyle Hunter retweeted
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial thorax.bmj.com/content/early…
The next Covid wave is going to be terrible. I wish we had a variant agnostic therapeutic to help. $hgen
22
Kyle Hunter retweeted
$HGEN big premarket spike right out of the gate, didn’t last long but might indicate where we are headed to say…
Can’t wait for the $hgen golf tournament. I need to get better
$hgen is going to give me blue balls if I don’t have the data by next week.
3
18
Congrats @humanigen! It is fantastic that NIH wants to work with you now on Long Covid. What a fantastic opportunity! Keep up the great work! $hgen #lenzilumab
seekingalpha.com/news/385537…
Kyle Hunter retweeted
"Why would the NIH post a 3rd party therapeutic journal entry on to their website for a drug that is currently awaiting TLD from the NIH?
"What is happening at the NIH?"
$HGEN
ncbi.nlm.nih.gov/research/co…
Hello everyone… obviously $hgen is a sacm company. The NIH is sharing the Thorax article on their website. Seems like a BIG sacm to me. 😂😂😂 great news everyone!
Kyle Hunter retweeted
$HGEN Nice!
LitCovid - NCBI - NLM - NIH ncbi.nlm.nih.gov/research/co…
Kyle Hunter retweeted
$HGEN this month!














